deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT00217165

Taurine as an Anti-Manic Agent: A Double-Blind, Placebo-Controlled Study

Taurine as an Anti-manic Agent: a Double-blind Placebo-controlled Study.

Sponsor: Mclean Hospital

Interventions taurine
Updated 9 times since 2017 Last updated: Feb 26, 2019 Started: Apr 30, 2005 Primary completion: Jan 31, 2010 Completion: Dec 31, 2011
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Bipolar Depression and Bipolar Disorder, this trial is completed. The trial is conducted by Mclean Hospital and has accumulated 9 data snapshots since 2005. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Study Description(click to expand)

Taurine is an amino acid that has some actions similar to mood stabilizers. Taurine is widely sold as a component of over-the-counter mood enhancing agents. However, controlled studies examining the mood effects of taurine are limited. An initial study in this laboratory looked at taurine's mood effects in individuals with bipolar disorder. This follow-up study is designed to further examine taurine's effects on manic symptoms. Subjects in the current follow-up study will add taurine or placebo to their current treatment regimen. Both depressive and manic symptoms will be tracked for three months to determine whether the addition of taurine affects mood symptoms.

Taurine is an amino acid that has some actions similar to mood stabilizers. Taurine is widely sold as a component of over-the-counter mood enhancing agents. However, controlled studies examining the mood effects of taurine are limited. An initial study in this laboratory looked at taurine's mood effects in individuals with bipolar disorder. This follow-up study is designed to further examine taurine's effects on manic symptoms. Subjects in the current follow-up study will add taurine or placebo to their current treatment regimen. Both depressive and manic symptoms will be tracked for three months to determine whether the addition of taurine affects mood symptoms.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshotCompleted~Apr 2017 – ~Jun 2018 · 14 months · monthly snapshotCompleted~Jun 2018 – ~Apr 2019 · 10 months · monthly snapshotCompleted~Apr 2019 – ~Jan 2021 · 21 months · monthly snapshotCompleted~Jan 2021 – ~Apr 2022 · 15 months · monthly snapshotCompleted~Apr 2022 – ~Jul 2024 · 27 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 19 months · monthly snapshotCompleted

Change History

9 versions recorded
  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Apr 2022 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Apr 2022 [monthly]

    Completed PHASE2

  5. Apr 2019 — Jan 2021 [monthly]

    Completed PHASE2

Show 4 earlier versions
  1. Jun 2018 — Apr 2019 [monthly]

    Completed PHASE2

  2. Apr 2017 — Jun 2018 [monthly]

    Completed PHASE2

  3. Feb 2017 — Apr 2017 [monthly]

    Completed PHASE2

  4. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Apr 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Mclean Hospital
Data source: Mclean Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations